Replies to post #47 on Cubist Pharmaceuticals, Inc. (CBST)

[genisi]

All I read In the SEC is "The Cubist product pipeline includes our lipopeptide program and our natural products screening program."
They are conducting several more clinical trials with Daptomycin but I don't see any news from their research collaboration with Ilypsa to develop a non-antibiotic therapy for Clostridium difficile associated diarrhea (CDAD).
Since they had discontinued the development of HepeX-B, I'm afraid they are still looking for new candidates in preclinical.